Abraham Weizman, MD
- 22Articles
- 65.2KReads
- 1997–2017Active
- 94Collaborators
- 203Citations
About
Abraham Weizman, MD, has contributed extensively to research on schizophrenia and schizoaffective disorders, neurodevelopmental conditions, and child and adolescent psychiatry. His publications address topics including inflammation in 22q11.2 deletion syndrome, synthetic cannabinoid use, antidepressant adherence, and pharmacologic treatments such as pregnenolone, dehydroepiandrosterone, and metadoxine. He has also investigated psychotropic drug use patterns, Tourette's disorder, and cognitive deficits associated with psychiatric conditions. His work spans from 1997 to 2017 and includes collaborations with authors such as Doron Gothelf and Haggai Hermesh.
Publications
Physicians Postgraduate Press, Inc. (PPP) makes no warranties about the accuracy or completeness of any information published in The Journal of Clinical Psychiatry or other PPP materials, and disclaims liability for any use or non-use of that information. Clinicians should not rely solely on these materials and should exercise their own professional judgment when making patient care decisions on an individualized basis.
